Trevi Therapeutics (TRVI) has announced its plans to initiate two pivotal Phase III trials for Haduvio, targeting IPF-related chronic cough, following a positive End-of-Phase 2 meeting with the FDA. The company reported a robust cash position of $188 million, which is expected to fund operations through 2028 and support key clinical milestones, including top-line data for upcoming trials. The trials will enroll approximately 300 and 130 patients, respectively, with the first trial set to begin in Q2 2026.
This development is significant as it positions Trevi to potentially become a leader in treating a condition with high unmet medical needs, especially given the lack of FDA-approved therapies for IPF-related chronic cough. The successful execution of these trials could lead to a New Drug Application (NDA) submission, further solidifying Trevi’s market presence.
Market professionals should closely monitor Trevi’s progress and the outcomes of these trials, as they could have substantial implications for the company’s valuation and the broader healthcare sector. For a deeper dive into Trevi’s strategic plans and clinical developments, I recommend checking out the full article.
Source: fool.com